Scandinavian Chemotech: Comment on rights issue outcome - Redeye

Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue. The offering was subscribed to 70.33% without having to utilise guarantee undertakings, and provides the company with cSEK8.7m in net proceeds. We argue that the outcome is solid and reiterate our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1016536/scandinavian-chemotech-comment-on-rights-issue-outcome?utm_source=finwire&utm_medium=RSS